I'd like to hear you talk about another point you raised, a very important one. It's about the value, over the next 10 years, of innovative drugs in oncology and immunology. Therapies are becoming more narrowly focused, and even individualized. Innovative molecules and drugs are going to become important.
Can you tell us more about this value?
It's as if we were looking at medicines strictly from the cost standpoint, when what we should be looking at is the therapeutic value and positive impacts not only on the patient, but also on the economy, system costs, and society as a whole.